Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Source: Inpharma, Volume 1, Number 1637, 2008-05-10 , pp. 2-2(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Bevacizumab, therapeutic use; Bristol-Myers-Squibb; Carboplatin, therapeutic use; Chugai-Pharmaceutical; Decision-Resources; Genentech; Healthcare-news; Ovarian-cancer, treatment; Paclitaxel, therapeutic use; Pharmaceutical-industry; Prescribing; Roche

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$34.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A